Penn Bioinvestor

Lexicon Pharmaceuticals: Stuck in Phase II?

Have to give you credit for a nice job this time, Vinny.

Hemispherx Biopharma Could Become a Nice Rebound Story

This VFC became more and more like a joke. You pump such a scam like HEB, shame on you. You kept bashing A.F., IMHO, he has much better knowledge in drug discovery than you. Go read his articles about HEB.

BioDelivery Sciences Opportunity, Beware Cel Sci Bashers

I am not an oncology expert, but my knowledge in biomedical research told me that the multi-kine program of CVM almost doomed even from its mechanism point of view. That why I said VFC, you are naive to pump this stock only based on a tour. You need to learn more about biomedical science first.

Antigenics Should Rise on the Promise of Cancer Immunotherapy Treatments

VFC, apparently you don't know much about drug discovery. This kind of pump for AGEN is simply naive. Put this way, yes, some previous biotech stocks you pumped do went up well, but it is NOT because you really understand the science behind, but simply because at that time, market is strong for biotech sector as a whole. Enough is enough, please stop here.

Cel-Sci's Targets Stay on Track

VFC, apparently you don't know much about drug discovery. Most of your posts are simply naive. Put this way, yes, some previous biotech stocks you pumped do went up well, but it is NOT because you really understand what is the science behind, but simply because at that time, market is strong for biotech sector as a whole. Please, stop this kind of joke.

BioSante Pharma's LibiGel: Big Upside Potential

Mike, I am not sure if you realized there is another experimental drug for HSDD in development by Vivus: Luramist (Testosterone MDTS), which is being developed to treat hypoactive sexual desire disorder in women, for which a Phase II study has been completed.

Investing in the Obesity Drug Basket

This Micheal Murphy guy is a joke. He kept pumping the stocks he own. He predicted early this year DNDN will go to $360/share very soon, which translate into about 40 billion market capital for this small biotech. (Shocked)

I just asked him yesterday if he will allow me to sell all my DNDN shares to him at $180/share, so he can make handsomely 2X on it.

I also challenged his pumping on ARNA: Safe? If doctors are looking for a low-risk solution, they might be better off prescribing diet and exercise changes than trying to eke out an additional 6- to 8-pound loss for a 200-pound person on lorcaserin (ARNA drug). LOL.

Put in this way, if a 200 pound person take ARNA's "wonderful' drug, by paying tens of thousands of dollars in two years, he shed off 4-6 pounds! Toxicology 101: EVERY DRUG IS TOXIC. why not take some diet, which is much safer. Game pretty much is over for ARNA, period.

I was shocked by his statement ARNA drug can be marketed together with Phen. Lack of basic drug approval knowledge: FDA will NEVER allow any such drug without all proper clinical trials.

BioMed News Bytes: Arena, ImmunoCellular, YM Bio

Totally agree with you, Mike. I bought VVUS at 3.5 early April, still holding. This is the winner. BTW, just want to stop by and say thank you for your research reports.
On Sep 21 10:07 AM Mike Havrilla wrote:

> I think VVUS has emerged as the front runner with ARNA / OREX both
> chasing. Will now be interesting to watch the deal flow for this
> trio of weight loss / obesity plays as they prepare for FDA submissions.
> Only wish I had more spare cash to invest in VVUS back in March when
> it was around 3 bucks:
> seekingalpha.com/artic...

Two Positive Notes for Arena Pharmaceuticals

This Michael Murphy predicted DNDN will go to $360/share very soon early this year. I just asked him if he will allow me to sell all my DNDN shares to him at $180/share, so he can make 2X on it.

What a great investor, LOL.

Anyway, You are a lot more objective than him, he is a disaster.

On Sep 19 01:34 PM Ruthanne Williams Roussel wrote:

> Certainly, I have an agenda, and I'll state it right here. My agenda
> is that I have a big beef with that Michael Murphy guy -- I understand
> he recommended ARNA but I didn't see it myself, so I may be wrong
> there. But my beef is that like many people who grew up listening
> to AM radio in the 70's, I can't stand that sappy song about the
> pony who got lost in the blizzard and the girl who went running "Wildfire."
>
>
> Seriously, I don't own any of these obesity stocks and I try to call
> 'em as I see 'em. I have also been known to modify my views over
> the months.

Buy The Obesity Drug Basket: ARNA, OREX, VVUS

BTW, did your DNDN reached $360/share now, mr. murphy? I can sell all shares to you for $180/share. LOL.

Buy The Obesity Drug Basket: ARNA, OREX, VVUS

Looks you have an agenda to post here? Doesn't looks like you are speaking the fact ARNA drug only produce merely 3.1% and 2% weight loss in two years!

Safe? If doctors are looking for a low-risk solution, they might be better off prescribing diet and exercise changes than trying to eke out an additional 6- to 8-pound loss for a 200-pound person on lorcaserin. LOL.

I just checked your previous posts, looks you are always an ARNA pumper, and you kept bashing VVUS, although tried your best to make you looks like fair and objective. You need to wake up from your fantasy. Game over for ARNA, period.

Buy The Obesity Drug Basket: ARNA, OREX, VVUS

By Brian Orelli
September 18, 2009

I'm really not sure what management said that got investors so excited; the data is lackluster at best. Lorcaserin might be strong enough to get approved, but it still pales in comparison to efficacy data released by VIVUS (Nasdaq: VVUS) and Orexigen Therapeutics (Nasdaq: OREX).

For instance, VIVUS' Qnexa resulted in weight loss of 11.0% and 10.4%, beating placebo by about 9 percentage points in two recently completed trials. Lorcaserin, on the other hand, resulted in a 5.9% reduction in body weight, a mere 3 or 4 percentage points better than placebo, depending on which patient group you look at. Comparing data across trials can be deceptive at best, but in this case I think we can call a qualitative winner.

Sure, the drug is safe. It doesn't seem to have the heart problems that plagued Wyeth's (NYSE: WYE) fen-phen or the psychiatric problems that plagued drugs from sanofi-aventis (NYSE: SNY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK). And management wants to argue that it'll be a first-line treatment for that reason alone.

But I have a hard time seeing doctors rushing to get their patients on lorcaserin when there may be other drugs on the market by then that help people shed so many more pounds. If doctors are looking for a low-risk solution, they might be better off prescribing diet and exercise changes than trying to eke out an additional 6- to 8-pound loss for a 200-pound person on lorcaserin.

There may be some smaller role for lorcaserin on the obesity market, just as there has been for other less-than-stellar diet drugs before it, but if you're looking for a blockbuster homerun, I'm not sure you'll find it in this Arena.

Is VVUS secondary offering similar story to HGSI, DNDN?

Justin,

Congratulate you for your many good calls and good luck to you too. Nice work, and I am following you.
On Sep 17 03:37 AM Justin M. Hall wrote:

> Penn:
>
> Dropping in to congratulate you for your call on VVUS. Nice work
> bro! Just so you know, I thought I had signed up to follow you awhile
> back and just realized that I had not. So, I'm doing it tonight.
>
>
> Congrats again!
>
> Justin

Two Positive Notes for Arena Pharmaceuticals

I just checked your previous posts, looks you are always an ARNA pumper, and you kept bashing VVUS, although tried your best to make you looks like fair and objective.

As to myself? I am a trader, never fall in love with any stocks and make big bucks all the time. You need to wake up from your fantasy. Game over for ARNA, period.

Two Positive Notes for Arena Pharmaceuticals

Looks you have an agenda to post here? Doesn't looks like you are speaking the fact ARNA drug only produce merely 3.1% and 2.2% weight loss in two years!

Safe? Eat food a few cal less everyday will produce a much better weight loss. LOL.